Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Prevalence of pseudoexfoliation syndrome in an isolated island population of Korea: The Woodo Study

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Venue: Poster Village: Pod 2

First Author: : S.Lee SOUTH KOREA

Co Author(s): :    E. Lee   H. Lee   J. Jeoung        

Abstract Details

Purpose:

To determine the prevalence and clinical characteristics of pseudoexfoliation syndrome (PXS) within Korean population living in Woodo island.

Setting:

Jeju National University Hospital

Methods:

339 individuals living in Woodo island of South Korea were recruited. This equited to 54.2 % of those aged 50 years or older within this district. Participants filled out questionnaires on life style. Intraocular pressure (IOP) and corneal endothelial cell function was measured. Both pupils were dilated. Fundus photos and stereo disc photos were taken. Vertical cup-to-disc (c/d) ratio was determined. Pure-tone audiometry (PTA) threshold was measured at 0.5, 1, 2, 4, and 6 kHz of frequencies for each ear.

Results:

The prevalence of PXS was 8.3% and bilaterality was 28.6%. The prevalence of PEX increased from 1.0% in among those 50 to 59 years old, to 7.3%, 15.9%, and 23.8% among those 60 to 69 years, 70 to 79 years, and over 80 years, respectively. PXS did not show significant association with alcohol consumption, smoking, outdoor activity, and occupation. PXS showed significant decrease in endothelial cell density. PXS did not show correlations with IOP, c/d ratio. PTA test revealed significant decrease in 1, 2 kHz in lens capsule PXS, and hearing loss showed laterality with lens capsule PXS.

Conclusions:

In Woodo island population of South Korea over 50 years old, the overall prevalence of PXS syndrome was 9.2%, and it increased with age. Decrease in corneal endothelial function and selective hearing loss was correlated in PXS patients.

Financial Disclosure:

NONE

Back to previous